Sermorelin vs CJC-1295: duration and design

GHRH analogs and the same receptor

Sermorelin and CJC-1295 are GHRH analogs, acting at the GHRH receptor on pituitary cells. The review of GHRH and its analogues describes that receptor biology and the downstream GH/IGF-1 system. Stimulation of the gland leaves physiological feedback operating.

The gland’s own role in responding is the design’s appeal. The next question is how that system behaves under the particular pattern of stimulation. Sharing a receptor gives these compounds a relationship, while their designs still need separate scrutiny.

Changes that prolong the signal

The native GHRH fragment clears quickly: the sermorelin pharmacokinetic study reported an intravenous plasma half-life of ~10–12 minutes. Longer-acting analogs were developed to resist that rapid loss. A change at position 2 reduces breakdown; CJC-1295 with DAC also binds albumin, a blood protein, extending persistence.

The drug-delivery review of GHRH analogs describes strategies for prolonging the action of this short-lived peptide family. DAC refers to the albumin-binding addition, so the full formulation name matters when duration is being discussed.

My interest in that engineering comes with a question about the response after exposure has been extended. Duration is something the molecule does. Improved function or fewer harms would be outcomes a trial needs to measure.

The continuous-infusion complication

The continuous GHRH(1-29) infusion study in six children recorded a response that rose early and then declined by 3 to 6 months, with complete GH suppression in one child. That experiment used a different delivery pattern and cannot settle a CJC-1295 comparison. It does undermine the casual assumption that prolonged stimulation necessarily buys a useful response.

A meaningful adult head-to-head trial would be a welcome follow-up. The papers listed here supply no trial that establishes a clinical winner. For now, the defensible comparison concerns the receptor, the design and the persistence; assigning superiority goes further.

Sports testing for both compounds

The magnetic-bead urine method targeted sermorelin, tesamorelin and CJC-1295. The later urine-screening procedure also included GHRH analogs and their metabolites. Both sermorelin and CJC-1295 are prohibited in tested sport.

That shared analytical setting can make the compounds appear interchangeable in a list of detected substances. It establishes a method’s targets. The sports-testing FAQ explains why detection, half-life and a clinical outcome remain distinct questions.